

# Dilan S Athauda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1722165/publications.pdf>

Version: 2024-02-01

22  
papers

1,172  
citations

623734

14  
h-index

713466

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1582  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyloid processing in <sc>COVID</sc>â€19â€ associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	3.9	35
2	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	1.9	9
3	The Impact of Type 2 Diabetes in Parkinson's Disease. Movement Disorders, 2022, 37, 1612-1623.	3.9	30
4	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs and Aging, 2021, 38, 355-373.	2.7	8
5	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsonâ€™s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The â€Exenatide-PD3â€™ study. BMJ Open, 2021, 11, e047993.	1.9	32
6	Diabetes medications and risk of Parkinsonâ€™s disease: a cohort study of patients with diabetes. Brain, 2020, 143, 3067-3076.	7.6	108
7	Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. Progress in Brain Research, 2020, 252, 493-523.	1.4	26
8	Diabetes, BMI, and Parkinson's. Movement Disorders, 2020, 35, 201-203.	3.9	14
9	Post hoc analysis of the Exenatideâ€PD</sc> trialâ€™Factors that predict response. European Journal of Neuroscience, 2019, 49, 410-421.	2.6	43
10	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
11	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
12	Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology, 2018, 136, 260-270.	4.1	68
13	Nanosopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells. ChemBioChem, 2018, 19, 2033-2038.	2.6	52
14	What Effects Might Exenatide have on Non-Motor Symptoms in Parkinsonâ€™s Disease: A Post Hoc Analysis. Journal of Parkinson's Disease, 2018, 8, 247-258.	2.8	47
15	GBA-Associated Parkinsonâ€™s Disease: Progression in a Deep Brain Stimulation Cohort. Journal of Parkinson's Disease, 2017, 7, 635-644.	2.8	44
16	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
17	Technologies Assessing Limb Bradykinesia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 65-77.	2.8	50
18	Cerebral air embolism during endoscopic retrograde cholangiopancreatography: treatment with therapeutic hypothermia. Endoscopy, 2014, 46, E151-E152.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Evolving Infarction in the Anterior Circulation. New England Journal of Medicine, 2014, 371, e20.	27.0	0
20	High Grade Glioma Mimicking Voltage Gated Potassium Channel Complex Associated Antibody Limbic Encephalitis. Case Reports in Neurological Medicine, 2014, 2014, 1-4.	0.4	6
21	A restless night's sleep. BMJ: British Medical Journal, 2012, 344, d8347-d8347.	2.3	1
22	Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.6	13